<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Biological therapy for inflammatory bowel disease,Gastroenterology,Gastroenterology,5-aminosalicylate,Abdominal pain,Achalasia,Acute pancreatitis,Adalimumab,Allergy,Anaphylaxis,Ankylosing spondylitis" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Biological therapy for inflammatory bowel disease - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Biological therapy for inflammatory bowel disease</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    	    <!-- start content -->
	    <div class="thumb tright">
<div class="thumbinner" style="width:202px;"><a href="../../../i/n/f/Image%7EInfliximab_structure2.jpg_d14b.html" class="internal" title="The anti-TNF-α monoclonal antibody infliximab is a major biological therapy for inflammatory bowel disease"><img src="../../../upload/thumb/5/5c/Infliximab_structure2.jpg/200px-Infliximab_structure2.jpg" alt="The anti-TNF-α monoclonal antibody infliximab is a major biological therapy for inflammatory bowel disease" width="200" height="142" longdesc="../../../i/n/f/Image%7EInfliximab_structure2.jpg_d14b.html" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify" style="float:right"><a href="../../../i/n/f/Image%7EInfliximab_structure2.jpg_d14b.html" class="internal" title="Enlarge"><img src="../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
The anti-<a href="../../../t/u/m/Tumor_necrosis_factor.html" title="Tumor necrosis factor">TNF-α</a> <a href="../../../m/o/n/Monoclonal_antibody.html" title="Monoclonal antibody">monoclonal antibody</a> <a href="../../../i/n/f/Infliximab.html" title="Infliximab">infliximab</a> is a major <b>biological therapy for inflammatory bowel disease</b></div>
</div>
</div>
<p><b>Biological therapy</b> refers to the use of medication that is tailored to specifically target an immune or genetic mediator of disease.<sup id="_ref-Staren_0" class="reference"><a href="#_note-Staren" title="">[1]</a></sup> Even for diseases of unknown cause, <a href="../../../m/o/l/Molecule.html" title="Molecule">molecules</a> that are involved in the disease process have been identified, and can be targeted for biological therapy; many of these molecules, which are mainly <a href="../../../c/y/t/Cytokine.html" title="Cytokine">cytokines</a>, are directly involved in the <a href="../../../i/m/m/Immune_system.html" title="Immune system">immune system</a>. <a href="../../../i/m/m/Immunotherapy.html" title="Immunotherapy">Biological therapy</a> has found a niche in the management of <a href="../../../c/a/n/Cancer.html" title="Cancer">cancer</a>,<sup id="_ref-Talpaz_0" class="reference"><a href="#_note-Talpaz" title="">[2]</a></sup><sup id="_ref-consortium_0" class="reference"><a href="#_note-consortium" title="">[3]</a></sup> <a href="../../../a/u/t/Autoimmune_disease.html" title="Autoimmune disease">autoimmune diseases</a>,<sup id="_ref-Enbrel_0" class="reference"><a href="#_note-Enbrel" title="">[4]</a></sup> and diseases of unknown cause that result in symptoms due to immune related mechanisms.<sup id="_ref-ACCENT1_0" class="reference"><a href="#_note-ACCENT1" title="">[5]</a></sup><sup id="_ref-ACT_0" class="reference"><a href="#_note-ACT" title="">[6]</a></sup></p>
<p>Inflammatory bowel disease, or <a href="../../../i/n/f/Inflammatory_bowel_disease.html" title="Inflammatory bowel disease">IBD</a>, is a collection of systemic <a href="../../../d/i/s/Disease.html" title="Disease">diseases</a> involving <a href="../../../i/n/f/Inflammation.html" title="Inflammation">inflammation</a> of the <a href="../../../g/a/s/Gastrointestinal_tract.html" title="Gastrointestinal tract">gastrointestinal tract</a>.<sup id="_ref-Hanauer_0" class="reference"><a href="#_note-Hanauer" title="">[7]</a></sup> IBD includes two (or three) diseases of unknown causation: <a href="../../../u/l/c/Ulcerative_colitis.html" title="Ulcerative colitis">ulcerative colitis</a>, which affects only the <a href="../../../c/o/l/Colon_%28anatomy%29.html" title="Colon (anatomy)">large bowel</a>; <a href="../../../c/r/o/Crohn%27s_disease.html" title="Crohn's disease">Crohn's disease</a>, which can affect the entire <a href="../../../g/a/s/Gastrointestinal_tract.html" title="Gastrointestinal tract">gastrointestinal tract</a>; and, indeterminate colitis, which consists of large bowel inflammation that shows elements of both Crohn's disease and ulcerative colitis.<sup id="_ref-Podolsky_0" class="reference"><a href="#_note-Podolsky" title="">[8]</a></sup> Although the causes of these diseases are unknown, genetic, environmental, immune and other mechanisms have been proposed. Of these, the immune system plays a large role in the development of symptoms.<sup id="_ref-Podolsky_1" class="reference"><a href="#_note-Podolsky" title="">[8]</a></sup> Given this, a variety of biological therapies have been developed for the treatment of these diseases. These have changed the way physicians treat Crohn's disease and ulcerative colitis.<sup id="_ref-ACCENT1_1" class="reference"><a href="#_note-ACCENT1" title="">[5]</a></sup><sup id="_ref-ACT_1" class="reference"><a href="#_note-ACT" title="">[6]</a></sup></p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Rationale_for_biological_therapy"><span class="tocnumber">1</span> <span class="toctext">Rationale for biological therapy</span></a></li>
<li class="toclevel-1"><a href="#Infliximab"><span class="tocnumber">2</span> <span class="toctext">Infliximab</span></a></li>
<li class="toclevel-1"><a href="#Other_monoclonal_antibodies"><span class="tocnumber">3</span> <span class="toctext">Other monoclonal antibodies</span></a></li>
<li class="toclevel-1"><a href="#Side_effects_and_concerns"><span class="tocnumber">4</span> <span class="toctext">Side effects and concerns</span></a></li>
<li class="toclevel-1"><a href="#Organisms"><span class="tocnumber">5</span> <span class="toctext">Organisms</span></a></li>
<li class="toclevel-1"><a href="#See_also"><span class="tocnumber">6</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">7</span> <span class="toctext">References</span></a></li>
</ul>
</td>
</tr>
</table>
<script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script>
<p><a name="Rationale_for_biological_therapy" id="Rationale_for_biological_therapy"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/o/Biological_therapy_for_inflammatory_bowel_disease.html" title="Edit section: Rationale for biological therapy">edit</a>]</span> <span class="mw-headline">Rationale for biological therapy</span></h2>
<div class="thumb tleft">
<div class="thumbinner" style="width:182px;"><a href="../../../c/y/t/Image%7ECytokines_in_IBD.jpg_c288.html" class="internal" title="Cytokines involved in IBD"><img src="../../../upload/thumb/c/c7/Cytokines_in_IBD.jpg/180px-Cytokines_in_IBD.jpg" alt="Cytokines involved in IBD" width="180" height="146" longdesc="../../../c/y/t/Image%7ECytokines_in_IBD.jpg_c288.html" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify" style="float:right"><a href="../../../c/y/t/Image%7ECytokines_in_IBD.jpg_c288.html" class="internal" title="Enlarge"><img src="../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
<a href="../../../c/y/t/Cytokine.html" title="Cytokine">Cytokines</a> involved in IBD</div>
</div>
</div>
<p><br />
Prior to the development of biological therapy as a modality to treat IBD, other medications that modulate the immune system -- including <a href="../../../5/-/a/5-aminosalicylate.html" title="5-aminosalicylate">5-aminosalicylates</a>, <a href="../../../p/r/e/Prednisone.html" title="Prednisone">steroids</a>, <a href="../../../a/z/a/Azathioprine.html" title="Azathioprine">azathioprine</a>, and other immunosuppressants -- were primarily used in treatment.<sup id="_ref-Hanauer_1" class="reference"><a href="#_note-Hanauer" title="">[7]</a></sup>. Patients with Crohn's disease that developed complications, including <a href="../../../f/i/s/Fistula.html" title="Fistula">fistulae</a>, or abnormal connections to the bowel, were treated with surgery.<sup id="_ref-Williams_0" class="reference"><a href="#_note-Williams" title="">[9]</a></sup> Patients with ulcerative colitis that does not respond to medications are still treated with <a href="../../../c/o/l/Colectomy.html" title="Colectomy">colectomy</a>, or removal of the <a href="../../../c/o/l/Colon_%28anatomy%29.html" title="Colon (anatomy)">colon</a>.</p>
<p>However, basic science research showed that there were many <a href="../../../c/y/t/Cytokine.html" title="Cytokine">cytokines</a> that were elevated in both Crohn's disease and ulcerative colitis.<sup id="_ref-APTReview_0" class="reference"><a href="#_note-APTReview" title="">[10]</a></sup> Crohn's disease cytokines, in general were lumped into the <i>Th1</i> classification of cytokines, and included <a href="../../../t/u/m/Tumour_necrosis_factor.html" title="Tumour necrosis factor">TNF-α</a>, <a href="../../../i/n/t/Interleukin.html" title="Interleukin">interleukin</a>-2, and <a href="../../../i/n/t/Interferon.html" title="Interferon">interferon</a> γ.<sup id="_ref-Romagagni_0" class="reference"><a href="#_note-Romagagni" title="">[11]</a></sup> Ulcerative colitis was less conclusively linked to the <i>Th2</i> pathway of cytokines.<sup id="_ref-Th2UC_0" class="reference"><a href="#_note-Th2UC" title="">[12]</a></sup></p>
<p><br /></p>
<p><a name="Infliximab" id="Infliximab"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/o/Biological_therapy_for_inflammatory_bowel_disease.html" title="Edit section: Infliximab">edit</a>]</span> <span class="mw-headline">Infliximab</span></h2>
<dl>
<dd>
<div class="noprint"><i>Main article: <a href="../../../i/n/f/Infliximab.html" title="Infliximab">Infliximab</a></i></div>
</dd>
</dl>
<p>The <a href="../../../m/o/n/Monoclonal_antibody.html" title="Monoclonal antibody">monoclonal antibody</a> <a href="../../../i/n/f/Infliximab.html" title="Infliximab">infliximab</a> is a mouse-human chimeric antibody to TNF-α. It first was used in the treatment of <a href="../../../r/h/e/Rheumatoid_arthritis.html" title="Rheumatoid arthritis">rheumatoid arthritis</a>,<sup id="_ref-InfliximabRA_0" class="reference"><a href="#_note-InfliximabRA" title="">[13]</a></sup> and was the first biological agent used in the treatment of IBD. It is also used in the treatment of <a href="../../../p/s/o/Psoriasis.html" title="Psoriasis">psoriasis</a> and <a href="../../../a/n/k/Ankylosing_spondylitis.html" title="Ankylosing spondylitis">ankylosing spondylitis</a>.<sup id="_ref-Psoriasis_0" class="reference"><a href="#_note-Psoriasis" title="">[14]</a></sup><sup id="_ref-AnkSpond_0" class="reference"><a href="#_note-AnkSpond" title="">[15]</a></sup> Infliximab has shown significant success in treating Crohn's disease.<sup id="_ref-ACCENT1_2" class="reference"><a href="#_note-ACCENT1" title="">[5]</a></sup></p>
<p><a name="Other_monoclonal_antibodies" id="Other_monoclonal_antibodies"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/o/Biological_therapy_for_inflammatory_bowel_disease.html" title="Edit section: Other monoclonal antibodies">edit</a>]</span> <span class="mw-headline">Other monoclonal antibodies</span></h2>
<p>Other biological therapy agents and monoclonal antibodies have not showed as much efficacy in the treatment of IBD. These include <a href="../../../e/t/a/Etanercept.html" title="Etanercept">etanercept</a> (which is the soluble <a href="../../../r/e/c/Receptor.html" title="Receptor">receptor</a> for <a href="../../../t/u/m/Tumour_necrosis_factor.html" title="Tumour necrosis factor">TNF</a>.<sup id="_ref-Etanercept_0" class="reference"><a href="#_note-Etanercept" title="">[16]</a></sup> <a href="../../../a/d/a/Adalimumab.html" title="Adalimumab">Adalimumab</a> (which is a humanized <a href="../../../r/e/c/Recombinant.html" title="Recombinant">recombinant</a> antibody to TNF) showed effectiveness in patients with moderate-to-severe Crohn's disease, but less than that of infliximab. <sup id="_ref-CLASSIC1_0" class="reference"><a href="#_note-CLASSIC1" title="">[17]</a></sup> It however conveys an advantage in that it is given by subcutaneous <a href="../../../i/n/j/Injection_%28medicine%29.html" title="Injection (medicine)">injection</a> as opposed to infliximab, which is given by <a href="../../../i/n/t/Intravenous.html" title="Intravenous">intravenous</a> infusion.</p>
<p>In 2005, two other recombinant medications were reported to have benefit in moderate to severe Crohn's disease. <a href="../../../c/e/r/Certolizumab_pegol.html" title="Certolizumab pegol">Certolizumab</a> is a <a href="../../../a/n/t/Antibody.html" title="Antibody">Fab</a> fragment of a humanized anti-<a href="../../../t/n/f/TNF_ce78.html" title="TNF">TNF alpha</a> <a href="../../../m/o/n/Monoclonal_antibody.html" title="Monoclonal antibody">monoclonal antibody</a> that is attached to <a href="../../../p/o/l/Polyethylene_glycol.html" title="Polyethylene glycol">polyethylene glycol</a> to increase its <a href="../../../h/a/l/Half-life.html" title="Half-life">half-life</a> in circulation. It was found to have eficacy over placebo medications for 10 weeks in the treatment of moderate to severe Crohn's disease in one large trial.<sup id="_ref-0" class="reference"><a href="#_note-0" title="">[18]</a></sup> <a href="../../../n/a/t/Natalizumab.html" title="Natalizumab">Natalizumab</a> is an anti-<a href="../../../i/n/t/Integrin.html" title="Integrin">integrin</a> monoclonal antibody that shown utility as induction and maintenance treatment for moderate to severe Crohn's disease.<sup id="_ref-1" class="reference"><a href="#_note-1" title="">[19]</a></sup> However, it has been associated with <a href="../../../p/r/o/Progressive_multifocal_leukoencephalopathy.html" title="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</a>, a usually fatal viral infection of the <a href="../../../b/r/a/Brain.html" title="Brain">brain</a>, that may limit its use.<sup id="_ref-2" class="reference"><a href="#_note-2" title="">[20]</a></sup></p>
<p><a name="Side_effects_and_concerns" id="Side_effects_and_concerns"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/o/Biological_therapy_for_inflammatory_bowel_disease.html" title="Edit section: Side effects and concerns">edit</a>]</span> <span class="mw-headline">Side effects and concerns</span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:102px;"><a href="../../../u/r/t/Image%7EUrticaria_2.jpg_0048.html" class="internal" title="Allergic reactions can occur with infliximab"><img src="../../../upload/thumb/5/5d/Urticaria_2.jpg/100px-Urticaria_2.jpg" alt="Allergic reactions can occur with infliximab" width="100" height="136" longdesc="../../../u/r/t/Image%7EUrticaria_2.jpg_0048.html" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify" style="float:right"><a href="../../../u/r/t/Image%7EUrticaria_2.jpg_0048.html" class="internal" title="Enlarge"><img src="../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
<a href="../../../a/l/l/Allergy.html" title="Allergy">Allergic</a> reactions can occur with <a href="../../../i/n/f/Infliximab.html" title="Infliximab">infliximab</a></div>
</div>
</div>
<p>There have been concerns about the <a href="../../../s/i/d/Side_effect.html" title="Side effect">side effects</a> of monoclonal antibodies, and specifically of infliximab, but these are rare. Early side effects include the risk of <a href="../../../a/l/l/Allergy.html" title="Allergy">allergic</a> reactions (including <a href="../../../a/n/a/Anaphylaxis.html" title="Anaphylaxis">anaphylaxis</a> which may be life-threatening), and reactions to the infusion. These are often treated with medications given before treatment. Infliximab also carries a risk of worsening infection, and can cause reactivation of old infections, like <a href="../../../t/u/b/Tuberculosis.html" title="Tuberculosis">tuberculosis</a>. Over time, there is the risk of <a href="../../../s/e/r/Serum_sickness.html" title="Serum sickness">serum sickness</a>, which is a delayed <a href="../../../h/y/p/Hypersensitivity.html" title="Hypersensitivity">hypersensitivity</a> response to the medication. Later complications may include <a href="../../../m/u/l/Multiple_sclerosis.html" title="Multiple sclerosis">multiple sclerosis</a> and <a href="../../../l/y/m/Lymphoma.html" title="Lymphoma">lymphoma</a>. Finally, the medication is quite expensive, with treatment costs ranging from US$3000 to $8000 per infusion.<sup id="_ref-GaryLichtenstein_0" class="reference"><a href="#_note-GaryLichtenstein" title="">[21]</a></sup><sup id="_ref-safety2_0" class="reference"><a href="#_note-safety2" title="">[22]</a></sup><sup id="_ref-safety3_0" class="reference"><a href="#_note-safety3" title="">[23]</a></sup></p>
<p>Loss of response to infliximab over time is a concern, due to the development of antibodies to infliximab (termed human anti-chimeric antibodies, or HACA). This can be reduced by concurrent treatment with other immunosuppressant medications (including <a href="../../../a/z/a/Azathioprine.html" title="Azathioprine">azathioprine</a> and <a href="../../../m/e/t/Methotrexate.html" title="Methotrexate">methotrexate</a>), by maintaining a regular infusion schedule, and by giving patients a pre-treatment dose of steroid medication.<sup id="_ref-HACA_0" class="reference"><a href="#_note-HACA" title="">[24]</a></sup></p>
<p><a name="Organisms" id="Organisms"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/o/Biological_therapy_for_inflammatory_bowel_disease.html" title="Edit section: Organisms">edit</a>]</span> <span class="mw-headline">Organisms</span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:152px;"><a href="../../../t/r/i/Image%7ETrichuris_egg.jpg_91ff.html" class="internal" title="Egg of Trichuris spp. whipworm.  Pig whipworm infection is thought to reduce Th1 cytokine levels in IBD."><img src="../../../upload/thumb/6/62/Trichuris_egg.jpg/150px-Trichuris_egg.jpg" alt="Egg of Trichuris spp. whipworm.  Pig whipworm infection is thought to reduce Th1 cytokine levels in IBD." width="150" height="100" longdesc="../../../t/r/i/Image%7ETrichuris_egg.jpg_91ff.html" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify" style="float:right"><a href="../../../t/r/i/Image%7ETrichuris_egg.jpg_91ff.html" class="internal" title="Enlarge"><img src="../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Egg of <i>Trichuris spp.</i> <a href="../../../w/h/i/Whipworm.html" title="Whipworm">whipworm</a>. Pig whipworm infection is thought to reduce Th1 <a href="../../../c/y/t/Cytokine.html" title="Cytokine">cytokine</a> levels in IBD.</div>
</div>
</div>
<p>It has been observed that patients in <a href="../../../n/o/r/North_America_e7c4.html" title="North America">North America</a> and <a href="../../../e/u/r/Europe.html" title="Europe">Europe</a> have higher rates of inflammatory bowel disease than patients in developing nations. One thought was that this was due to the protective effects of organisms colonizing the colon in developing countries. On the basis of this, the pig whipworm, <i><a href="../../../w/h/i/Whipworm.html" title="Whipworm">Trichuris suis</a></i>, which causes minimal disease in humans, was evaluated in both Crohn's disease and ulcerative colitis, and showed effect in an open label and randomized control trial respectively.<sup id="_ref-TrichurisCD_0" class="reference"><a href="#_note-TrichurisCD" title="">[25]</a></sup><sup id="_ref-TrichurisUC_0" class="reference"><a href="#_note-TrichurisUC" title="">[26]</a></sup>The hypothesis is that the whipworm protects against Th1 cytokines, despite its effectiveness in ulcerative colitis (thought to be Th2 mediated). The theory that early exposure to infections protects against IBD has been termed the <i><a href="../../../h/y/g/Hygiene_hypothesis.html" title="Hygiene hypothesis">hygiene hypothesis</a></i>.<sup id="_ref-Manitoba_0" class="reference"><a href="#_note-Manitoba" title="">[27]</a></sup></p>
<p><a name="See_also" id="See_also"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/o/Biological_therapy_for_inflammatory_bowel_disease.html" title="Edit section: See also">edit</a>]</span> <span class="mw-headline">See also</span></h2>
<ul>
<li><a href="../../../n/o/m/Nomenclature_of_monoclonal_antibodies.html" title="Nomenclature of monoclonal antibodies">Nomenclature of monoclonal antibodies</a></li>
</ul>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/o/Biological_therapy_for_inflammatory_bowel_disease.html" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<div class="references-small">
<ol class="references">
<li id="_note-Staren"><b><a href="#_ref-Staren_0" title="">^</a></b> <cite style="font-style:normal">Staren E, Essner R, Economou J (1989). "Overview of biological response modifiers.". <i>Semin Surg Oncol</i> <b>5</b> (6): 379-84. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2480627" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2480627">PMID 2480627</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Overview+of+biological+response+modifiers.&amp;rft.title=Semin+Surg+Oncol&amp;rft.jtitle=Semin+Surg+Oncol&amp;rft.date=1989&amp;rft.volume=5&amp;rft.issue=6&amp;rft.au=Staren+E%2C+Essner+R%2C+Economou+J&amp;rft.pages=379-84">&#160;</span></li>
<li id="_note-Talpaz"><b><a href="#_ref-Talpaz_0" title="">^</a></b> <cite style="font-style:normal">Talpaz M, Kantarjian H, McCredie K, Trujillo J, Keating M, Gutterman J (1987). "Therapy of chronic myelogenous leukemia.". <i>Cancer</i> <b>59</b> (3 Suppl): 664-7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10822467" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10822467">PMID 10822467</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Therapy+of+chronic+myelogenous+leukemia.&amp;rft.title=Cancer&amp;rft.jtitle=Cancer&amp;rft.date=1987&amp;rft.volume=59&amp;rft.issue=3+Suppl&amp;rft.au=Talpaz+M%2C+Kantarjian+H%2C+McCredie+K%2C+Trujillo+J%2C+Keating+M%2C+Gutterman+J&amp;rft.pages=664-7">&#160;</span></li>
<li id="_note-consortium"><b><a href="#_ref-consortium_0" title="">^</a></b> <cite style="font-style:normal">Kalinski P, Mapara M (2006). "9th Annual Meeting of the Regional Cancer Consortium for the Biological Therapy of Cancer. 16-18 February 2006, UPMC Herberman Conference Center, Pittsburgh, PA, USA.". <i>Expert Opin Biol Ther</i> <b>6</b> (6): 631-3. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16706609" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16706609">PMID 16706609</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=9th+Annual+Meeting+of+the+Regional+Cancer+Consortium+for+the+Biological+Therapy+of+Cancer.+16-18+February+2006%2C+UPMC+Herberman+Conference+Center%2C+Pittsburgh%2C+PA%2C+USA.&amp;rft.title=Expert+Opin+Biol+Ther&amp;rft.jtitle=Expert+Opin+Biol+Ther&amp;rft.date=2006&amp;rft.volume=6&amp;rft.issue=6&amp;rft.au=Kalinski+P%2C+Mapara+M&amp;rft.pages=631-3">&#160;</span></li>
<li id="_note-Enbrel"><b><a href="#_ref-Enbrel_0" title="">^</a></b> <cite style="font-style:normal">Weinblatt M, Kremer J, Bankhurst A, Bulpitt K, Fleischmann R, Fox R, Jackson C, Lange M, Burge D (1999). "A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.". <i>N Engl J Med</i> <b>340</b> (4): 253-9. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9920948" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9920948">PMID 9920948</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=A+trial+of+etanercept%2C+a+recombinant+tumor+necrosis+factor+receptor%3A+Fc+fusion+protein%2C+in+patients+with+rheumatoid+arthritis+receiving+methotrexate.&amp;rft.title=N+Engl+J+Med&amp;rft.jtitle=N+Engl+J+Med&amp;rft.date=1999&amp;rft.volume=340&amp;rft.issue=4&amp;rft.au=Weinblatt+M%2C+Kremer+J%2C+Bankhurst+A%2C+Bulpitt+K%2C+Fleischmann+R%2C+Fox+R%2C+Jackson+C%2C+Lange+M%2C+Burge+D&amp;rft.pages=253-9">&#160;</span></li>
<li id="_note-ACCENT1">^ <a href="#_ref-ACCENT1_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-ACCENT1_1" title=""><sup><i><b>b</b></i></sup></a> <a href="#_ref-ACCENT1_2" title=""><sup><i><b>c</b></i></sup></a> <cite style="font-style:normal">Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J, Rachmilewitz D, Wolf D, Olson A, Bao W, Rutgeerts P (2002). "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.". <i>Lancet</i> <b>359</b> (9317): 1541-9. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12047962" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12047962">PMID 12047962</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Maintenance+infliximab+for+Crohn%27s+disease%3A+the+ACCENT+I+randomised+trial.&amp;rft.title=Lancet&amp;rft.jtitle=Lancet&amp;rft.date=2002&amp;rft.volume=359&amp;rft.issue=9317&amp;rft.au=Hanauer+S%2C+Feagan+B%2C+Lichtenstein+G%2C+Mayer+L%2C+Schreiber+S%2C+Colombel+J%2C+Rachmilewitz+D%2C+Wolf+D%2C+Olson+A%2C+Bao+W%2C+Rutgeerts+P&amp;rft.pages=1541-9">&#160;</span></li>
<li id="_note-ACT">^ <a href="#_ref-ACT_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-ACT_1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal">Rutgeerts P, Sandborn W, Feagan B, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer S, Lichtenstein G, de Villiers W, Present D, Sands B, Colombel J (2005). "Infliximab for induction and maintenance therapy for ulcerative colitis.". <i>N Engl J Med</i> <b>353</b> (23): 2462-76. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16339095" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16339095">PMID 16339095</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Infliximab+for+induction+and+maintenance+therapy+for+ulcerative+colitis.&amp;rft.title=N+Engl+J+Med&amp;rft.jtitle=N+Engl+J+Med&amp;rft.date=2005&amp;rft.volume=353&amp;rft.issue=23&amp;rft.au=Rutgeerts+P%2C+Sandborn+W%2C+Feagan+B%2C+Reinisch+W%2C+Olson+A%2C+Johanns+J%2C+Travers+S%2C+Rachmilewitz+D%2C+Hanauer+S%2C+Lichtenstein+G%2C+de+Villiers+W%2C+Present+D%2C+Sands+B%2C+Colombel+J&amp;rft.pages=2462-76">&#160;</span></li>
<li id="_note-Hanauer">^ <a href="#_ref-Hanauer_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Hanauer_1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal">Hanauer, Stephen B. (March 1996). "<a href="http://content.nejm.org/cgi/content/extract/334/13/841" class="external text" title="http://content.nejm.org/cgi/content/extract/334/13/841" rel="nofollow">Inflammatory bowel disease</a>". <i>New England Journal of Medicine</i> <b>334</b> (13): 841-848. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8596552" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8596552">PMID 8596552</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Inflammatory+bowel+disease&amp;rft.title=New+England+Journal+of+Medicine&amp;rft.jtitle=New+England+Journal+of+Medicine&amp;rft.date=1996&amp;rft.volume=334&amp;rft.issue=13&amp;rft.aulast=Hanauer&amp;rft.aufirst=Stephen+B.&amp;rft.pages=841-848&amp;rft_id=http%3A%2F%2Fcontent.nejm.org%2Fcgi%2Fcontent%2Fextract%2F334%2F13%2F841">&#160;</span></li>
<li id="_note-Podolsky">^ <a href="#_ref-Podolsky_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Podolsky_1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal">Podolsky, Daniel K. (August 2002). "<a href="http://content.nejm.org/cgi/content/extract/347/6/417" class="external text" title="http://content.nejm.org/cgi/content/extract/347/6/417" rel="nofollow">Inflammatory bowel disease</a>". <i>New England Journal of Medicine</i> <b>346</b> (6): 417-29. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12167685" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12167685">PMID 12167685</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Inflammatory+bowel+disease&amp;rft.title=New+England+Journal+of+Medicine&amp;rft.jtitle=New+England+Journal+of+Medicine&amp;rft.date=2002&amp;rft.volume=346&amp;rft.issue=6&amp;rft.aulast=Podolsky&amp;rft.aufirst=Daniel+K.&amp;rft.pages=417-29&amp;rft_id=http%3A%2F%2Fcontent.nejm.org%2Fcgi%2Fcontent%2Fextract%2F347%2F6%2F417">&#160;</span></li>
<li id="_note-Williams"><b><a href="#_ref-Williams_0" title="">^</a></b> <cite style="font-style:normal">Williams J (1971). "The place of surgery in Crohn's disease.". <i>Gut</i> <b>12</b> (9): 739-49. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4938523" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4938523">PMID 4938523</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=The+place+of+surgery+in+Crohn%27s+disease.&amp;rft.title=Gut&amp;rft.jtitle=Gut&amp;rft.date=1971&amp;rft.volume=12&amp;rft.issue=9&amp;rft.au=Williams+J&amp;rft.pages=739-49">&#160;</span></li>
<li id="_note-APTReview"><b><a href="#_ref-APTReview_0" title="">^</a></b> <cite style="font-style:normal">Pallone F, Monteleone G. "Regulatory cytokines in inflammatory bowel disease.". <i>Aliment Pharmacol Ther</i> <b>10 Suppl 2</b>: 75-9; discussion 80. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8899105" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8899105">PMID 8899105</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Regulatory+cytokines+in+inflammatory+bowel+disease.&amp;rft.title=Aliment+Pharmacol+Ther&amp;rft.jtitle=Aliment+Pharmacol+Ther&amp;rft.volume=10+Suppl+2&amp;rft.au=Pallone+F%2C+Monteleone+G&amp;rft.pages=75-9%3B+discussion+80">&#160;</span></li>
<li id="_note-Romagagni"><b><a href="#_ref-Romagagni_0" title="">^</a></b> <cite style="font-style:normal">Romagnani S (1999). "Th1/Th2 cells.". <i>Inflamm Bowel Dis</i> <b>5</b> (4): 285-94. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10579123" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10579123">PMID 10579123</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Th1%2FTh2+cells.&amp;rft.title=Inflamm+Bowel+Dis&amp;rft.jtitle=Inflamm+Bowel+Dis&amp;rft.date=1999&amp;rft.volume=5&amp;rft.issue=4&amp;rft.au=Romagnani+S&amp;rft.pages=285-94">&#160;</span></li>
<li id="_note-Th2UC"><b><a href="#_ref-Th2UC_0" title="">^</a></b> <cite style="font-style:normal">Inoue S, Matsumoto T, Iida M, Mizuno M, Kuroki F, Hoshika K, Shimizu M (1999). "Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity.". <i>Am J Gastroenterol</i> <b>94</b> (9): 2441-6. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10484006" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10484006">PMID 10484006</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Characterization+of+cytokine+expression+in+the+rectal+mucosa+of+ulcerative+colitis%3A+correlation+with+disease+activity.&amp;rft.title=Am+J+Gastroenterol&amp;rft.jtitle=Am+J+Gastroenterol&amp;rft.date=1999&amp;rft.volume=94&amp;rft.issue=9&amp;rft.au=Inoue+S%2C+Matsumoto+T%2C+Iida+M%2C+Mizuno+M%2C+Kuroki+F%2C+Hoshika+K%2C+Shimizu+M&amp;rft.pages=2441-6">&#160;</span></li>
<li id="_note-InfliximabRA"><b><a href="#_ref-InfliximabRA_0" title="">^</a></b> <cite style="font-style:normal">Elliott M, Maini R, Feldmann M, Kalden J, Antoni C, Smolen J, Leeb B, Breedveld F, Macfarlane J, Bijl H (1994). "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.". <i>Lancet</i> <b>344</b> (8930): 1105-10. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7934491" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7934491">PMID 7934491</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Randomised+double-blind+comparison+of+chimeric+monoclonal+antibody+to+tumour+necrosis+factor+alpha+%28cA2%29+versus+placebo+in+rheumatoid+arthritis.&amp;rft.title=Lancet&amp;rft.jtitle=Lancet&amp;rft.date=1994&amp;rft.volume=344&amp;rft.issue=8930&amp;rft.au=Elliott+M%2C+Maini+R%2C+Feldmann+M%2C+Kalden+J%2C+Antoni+C%2C+Smolen+J%2C+Leeb+B%2C+Breedveld+F%2C+Macfarlane+J%2C+Bijl+H&amp;rft.pages=1105-10">&#160;</span></li>
<li id="_note-Psoriasis"><b><a href="#_ref-Psoriasis_0" title="">^</a></b> <cite style="font-style:normal">Chaudhari U, Romano P, Mulcahy L, Dooley L, Baker D, Gottlieb A (2001). "Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.". <i>Lancet</i> <b>357</b> (9271): 1842-7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11410193" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11410193">PMID 11410193</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Efficacy+and+safety+of+infliximab+monotherapy+for+plaque-type+psoriasis%3A+a+randomised+trial.&amp;rft.title=Lancet&amp;rft.jtitle=Lancet&amp;rft.date=2001&amp;rft.volume=357&amp;rft.issue=9271&amp;rft.au=Chaudhari+U%2C+Romano+P%2C+Mulcahy+L%2C+Dooley+L%2C+Baker+D%2C+Gottlieb+A&amp;rft.pages=1842-7">&#160;</span></li>
<li id="_note-AnkSpond"><b><a href="#_ref-AnkSpond_0" title="">^</a></b> <cite style="font-style:normal">Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J (2002). "Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.". <i>Lancet</i> <b>359</b> (9313): 1187-93. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11955536" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11955536">PMID 11955536</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Treatment+of+active+ankylosing+spondylitis+with+infliximab%3A+a+randomised+controlled+multicentre+trial.&amp;rft.title=Lancet&amp;rft.jtitle=Lancet&amp;rft.date=2002&amp;rft.volume=359&amp;rft.issue=9313&amp;rft.au=Braun+J%2C+Brandt+J%2C+Listing+J%2C+Zink+A%2C+Alten+R%2C+Golder+W%2C+Gromnica-Ihle+E%2C+Kellner+H%2C+Krause+A%2C+Schneider+M%2C+S%C3%B6rensen+H%2C+Zeidler+H%2C+Thriene+W%2C+Sieper+J&amp;rft.pages=1187-93">&#160;</span></li>
<li id="_note-Etanercept"><b><a href="#_ref-Etanercept_0" title="">^</a></b> <cite style="font-style:normal">Sandborn W, Hanauer S, Katz S, Safdi M, Wolf D, Baerg R, Tremaine W, Johnson T, Diehl N, Zinsmeister A (2001). "Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.". <i>Gastroenterology</i> <b>121</b> (5): 1088-94. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11677200" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11677200">PMID 11677200</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Etanercept+for+active+Crohn%27s+disease%3A+a+randomized%2C+double-blind%2C+placebo-controlled+trial.&amp;rft.title=Gastroenterology&amp;rft.jtitle=Gastroenterology&amp;rft.date=2001&amp;rft.volume=121&amp;rft.issue=5&amp;rft.au=Sandborn+W%2C+Hanauer+S%2C+Katz+S%2C+Safdi+M%2C+Wolf+D%2C+Baerg+R%2C+Tremaine+W%2C+Johnson+T%2C+Diehl+N%2C+Zinsmeister+A&amp;rft.pages=1088-94">&#160;</span></li>
<li id="_note-CLASSIC1"><b><a href="#_ref-CLASSIC1_0" title="">^</a></b> <cite style="font-style:normal">Hanauer S, Sandborn W, Rutgeerts P, Fedorak R, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P (2006). "Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.". <i>Gastroenterology</i> <b>130</b> (2): 323-33; quiz 591. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16472588" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16472588">PMID 16472588</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Human+anti-tumor+necrosis+factor+monoclonal+antibody+%28adalimumab%29+in+Crohn%27s+disease%3A+the+CLASSIC-I+trial.&amp;rft.title=Gastroenterology&amp;rft.jtitle=Gastroenterology&amp;rft.date=2006&amp;rft.volume=130&amp;rft.issue=2&amp;rft.au=Hanauer+S%2C+Sandborn+W%2C+Rutgeerts+P%2C+Fedorak+R%2C+Lukas+M%2C+MacIntosh+D%2C+Panaccione+R%2C+Wolf+D%2C+Pollack+P&amp;rft.pages=323-33%3B+quiz+591">&#160;</span></li>
<li id="_note-0"><b><a href="#_ref-0" title="">^</a></b> <cite style="font-style:normal">Schreiber S, Rutgeerts P, Fedorak R, Khaliq-Kareemi M, Kamm M, Boivin M, Bernstein C, Staun M, Thomsen O, Innes A (2005). "A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.". <i>Gastroenterology</i> <b>129</b> (3): 807-18. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16143120" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16143120">PMID 16143120</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=A+randomized%2C+placebo-controlled+trial+of+certolizumab+pegol+%28CDP870%29+for+treatment+of+Crohn%27s+disease.&amp;rft.title=Gastroenterology&amp;rft.jtitle=Gastroenterology&amp;rft.date=2005&amp;rft.volume=129&amp;rft.issue=3&amp;rft.au=Schreiber+S%2C+Rutgeerts+P%2C+Fedorak+R%2C+Khaliq-Kareemi+M%2C+Kamm+M%2C+Boivin+M%2C+Bernstein+C%2C+Staun+M%2C+Thomsen+O%2C+Innes+A&amp;rft.pages=807-18">&#160;</span></li>
<li id="_note-1"><b><a href="#_ref-1" title="">^</a></b> <cite style="font-style:normal">Sandborn W, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge G, Rutgeerts P (2005). "Natalizumab induction and maintenance therapy for Crohn's disease.". <i>N Engl J Med</i> <b>353</b> (18): 1912-25. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16267322" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16267322">PMID 16267322</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Natalizumab+induction+and+maintenance+therapy+for+Crohn%27s+disease.&amp;rft.title=N+Engl+J+Med&amp;rft.jtitle=N+Engl+J+Med&amp;rft.date=2005&amp;rft.volume=353&amp;rft.issue=18&amp;rft.au=Sandborn+W%2C+Colombel+J%2C+Enns+R%2C+Feagan+B%2C+Hanauer+S%2C+Lawrance+I%2C+Panaccione+R%2C+Sanders+M%2C+Schreiber+S%2C+Targan+S%2C+van+Deventer+S%2C+Goldblum+R%2C+Despain+D%2C+Hogge+G%2C+Rutgeerts+P&amp;rft.pages=1912-25">&#160;</span></li>
<li id="_note-2"><b><a href="#_ref-2" title="">^</a></b> <cite style="font-style:normal">Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P (2005). "Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.". <i>N Engl J Med</i> <b>353</b> (4): 362-8. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15947080" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15947080">PMID 15947080</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Progressive+multifocal+leukoencephalopathy+after+natalizumab+therapy+for+Crohn%27s+disease.&amp;rft.title=N+Engl+J+Med&amp;rft.jtitle=N+Engl+J+Med&amp;rft.date=2005&amp;rft.volume=353&amp;rft.issue=4&amp;rft.au=Van+Assche+G%2C+Van+Ranst+M%2C+Sciot+R%2C+Dubois+B%2C+Vermeire+S%2C+Noman+M%2C+Verbeeck+J%2C+Geboes+K%2C+Robberecht+W%2C+Rutgeerts+P&amp;rft.pages=362-8">&#160;</span></li>
<li id="_note-GaryLichtenstein"><b><a href="#_ref-GaryLichtenstein_0" title="">^</a></b> <cite style="font-style:normal">Blonski W, Lichtenstein G (2006). "Safety of biologics in inflammatory bowel disease.". <i>Curr Treat Options Gastroenterol</i> <b>9</b> (3): 221-33. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16901386" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16901386">PMID 16901386</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Safety+of+biologics+in+inflammatory+bowel+disease.&amp;rft.title=Curr+Treat+Options+Gastroenterol&amp;rft.jtitle=Curr+Treat+Options+Gastroenterol&amp;rft.date=2006&amp;rft.volume=9&amp;rft.issue=3&amp;rft.au=Blonski+W%2C+Lichtenstein+G&amp;rft.pages=221-33">&#160;</span></li>
<li id="_note-safety2"><b><a href="#_ref-safety2_0" title="">^</a></b> <cite style="font-style:normal">Rutgeerts P, Van Assche G, Vermeire S (2006). "Review article: Infliximab therapy for inflammatory bowel disease--seven years on.". <i>Aliment Pharmacol Ther</i> <b>23</b> (4): 451-63. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16441465" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16441465">PMID 16441465</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Review+article%3A+Infliximab+therapy+for+inflammatory+bowel+disease--seven+years+on.&amp;rft.title=Aliment+Pharmacol+Ther&amp;rft.jtitle=Aliment+Pharmacol+Ther&amp;rft.date=2006&amp;rft.volume=23&amp;rft.issue=4&amp;rft.au=Rutgeerts+P%2C+Van+Assche+G%2C+Vermeire+S&amp;rft.pages=451-63">&#160;</span></li>
<li id="_note-safety3"><b><a href="#_ref-safety3_0" title="">^</a></b> <cite style="font-style:normal">Siegel C, Hur C, Korzenik J, Gazelle G, Sands B (2006). "Risks and benefits of infliximab for the treatment of Crohn's disease.". <i>Clin Gastroenterol Hepatol</i> <b>4</b> (8): 1017-24; quiz 976. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16843733" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16843733">PMID 16843733</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Risks+and+benefits+of+infliximab+for+the+treatment+of+Crohn%27s+disease.&amp;rft.title=Clin+Gastroenterol+Hepatol&amp;rft.jtitle=Clin+Gastroenterol+Hepatol&amp;rft.date=2006&amp;rft.volume=4&amp;rft.issue=8&amp;rft.au=Siegel+C%2C+Hur+C%2C+Korzenik+J%2C+Gazelle+G%2C+Sands+B&amp;rft.pages=1017-24%3B+quiz+976">&#160;</span></li>
<li id="_note-HACA"><b><a href="#_ref-HACA_0" title="">^</a></b> <cite style="font-style:normal">Sandborn W (2003). "Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease.". <i>Curr Gastroenterol Rep</i> <b>5</b> (6): 501-5. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14602060" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14602060">PMID 14602060</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Optimizing+anti-tumor+necrosis+factor+strategies+in+inflammatory+bowel+disease.&amp;rft.title=Curr+Gastroenterol+Rep&amp;rft.jtitle=Curr+Gastroenterol+Rep&amp;rft.date=2003&amp;rft.volume=5&amp;rft.issue=6&amp;rft.au=Sandborn+W&amp;rft.pages=501-5">&#160;</span></li>
<li id="_note-TrichurisCD"><b><a href="#_ref-TrichurisCD_0" title="">^</a></b> <cite style="font-style:normal">Summers R, Elliott D, Urban J, Thompson R, Weinstock J (2005). "Trichuris suis therapy in Crohn's disease.". <i>Gut</i> <b>54</b> (1): 87-90. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15591509" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15591509">PMID 15591509</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Trichuris+suis+therapy+in+Crohn%27s+disease.&amp;rft.title=Gut&amp;rft.jtitle=Gut&amp;rft.date=2005&amp;rft.volume=54&amp;rft.issue=1&amp;rft.au=Summers+R%2C+Elliott+D%2C+Urban+J%2C+Thompson+R%2C+Weinstock+J&amp;rft.pages=87-90">&#160;</span></li>
<li id="_note-TrichurisUC"><b><a href="#_ref-TrichurisUC_0" title="">^</a></b> <cite style="font-style:normal">Summers R, Elliott D, Urban J, Thompson R, Weinstock J (2005). "Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial.". <i>Gastroenterology</i> <b>128</b> (4): 825-32. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15825065" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15825065">PMID 15825065</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Trichuris+suis+therapy+for+active+ulcerative+colitis%3A+a+randomized+controlled+trial.&amp;rft.title=Gastroenterology&amp;rft.jtitle=Gastroenterology&amp;rft.date=2005&amp;rft.volume=128&amp;rft.issue=4&amp;rft.au=Summers+R%2C+Elliott+D%2C+Urban+J%2C+Thompson+R%2C+Weinstock+J&amp;rft.pages=825-32">&#160;</span></li>
<li id="_note-Manitoba"><b><a href="#_ref-Manitoba_0" title="">^</a></b> <cite style="font-style:normal">Green C, Elliott L, Beaudoin C, Bernstein CN.. "A Population-based Ecologic Study of Inflammatory Bowel Disease: Searching for Etiologic Clues.". <i>Am J Epidemiol</i>. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16920784" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16920784">PMID 16920784</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=A+Population-based+Ecologic+Study+of+Inflammatory+Bowel+Disease%3A+Searching+for+Etiologic+Clues.&amp;rft.title=Am+J+Epidemiol&amp;rft.jtitle=Am+J+Epidemiol&amp;rft.au=Green+C%2C+Elliott+L%2C+Beaudoin+C%2C+Bernstein+CN.">&#160;</span></li>
</ol>
</div>
<table class="navbox collapsible autocollapse" style="margin:auto;">
<tr>
<th colspan="2" style="text-align:center;">
<div style="float:left; width:6em; text-align:left;">
<div class="noprint plainlinksneverexpand" style="background-color:transparent; padding:0; font-weight:normal; font-size:xx-small; color:#000000; white-space:nowrap;"><a href="../../../g/a/s/Template%7EGastroenterology_b0c8.html" title="Template:Gastroenterology"><span title="View this template">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="../../../g/a/s/Template_talk%7EGastroenterology_ae9a.html" title="Template talk:Gastroenterology"><span title="Discussion about this template">d</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org../../../g/a/s/Template%7EGastroenterology_b0c8.html" class="external text" title="http://en.wikipedia.org../../../g/a/s/Template%7EGastroenterology_b0c8.html" rel="nofollow"><span style="color: #002bb8;" title="You can edit this template. Please use the preview button before saving.">e</span></a></div>
</div>
<span style="font-size:110%;"><a href="../../../h/e/a/Health_science.html" title="Health science">Health science</a> - <a href="../../../m/e/d/Medicine.html" title="Medicine">Medicine</a> - <a href="../../../g/a/s/Gastroenterology.html" title="Gastroenterology">Gastroenterology</a> (primarily <a href="../../../d/i/s/ICD-10_Chapter_XI%7E_Diseases_of_the_digestive_system_615e.html" title="ICD-10 Chapter XI: Diseases of the digestive system">K</a>)</span></th>
</tr>
<tr>
<th style=""><a href="../../../e/s/o/Esophagus.html" title="Esophagus">esophagus</a> - <a href="../../../s/t/o/Stomach.html" title="Stomach">stomach</a>:</th>
<td style="" colspan="1"><a href="../../../h/a/l/Halitosis.html" title="Halitosis">Halitosis</a>&#160;| <a href="../../../n/a/u/Nausea.html" title="Nausea">Nausea</a>&#160;| <a href="../../../v/o/m/Vomiting.html" title="Vomiting">Vomiting</a>&#160;| <a href="../../../h/e/a/Heartburn.html" title="Heartburn">Heartburn</a>&#160;| <a href="../../../g/a/s/Gastroesophageal_reflux_disease.html" title="Gastroesophageal reflux disease">GERD</a>&#160;| <a href="../../../a/c/h/Achalasia.html" title="Achalasia">Achalasia</a>&#160;| <a href="../../../e/s/o/Esophageal_cancer.html" title="Esophageal cancer">Esophageal&#160;cancer</a>&#160;| <a href="../../../e/s/o/Esophageal_varices.html" title="Esophageal varices">Esophageal&#160;varices</a>&#160;| <a href="../../../p/e/p/Peptic_ulcer.html" title="Peptic ulcer">Peptic&#160;ulcer</a>&#160;| <a href="../../../a/b/d/Abdominal_pain.html" title="Abdominal pain">Abdominal&#160;pain</a>&#160;| <a href="../../../s/t/o/Stomach_cancer.html" title="Stomach cancer">Stomach cancer</a>&#160;| <a href="../../../f/u/n/Functional_dyspepsia.html" title="Functional dyspepsia">Non-ulcer&#160;dyspepsia</a>&#160;| <a href="../../../g/a/s/Gastroparesis.html" title="Gastroparesis">Gastroparesis</a></td>
</tr>
<tr>
<th style=""><a href="../../../l/i/v/Liver.html" title="Liver">liver</a> - <a href="../../../p/a/n/Pancreas.html" title="Pancreas">pancreas</a> - <a href="../../../g/a/l/Gallbladder.html" title="Gallbladder">gallbladder</a> - <a href="../../../b/i/l/Biliary_tree.html" title="Biliary tree">biliary tree</a>:</th>
<td style="" colspan="1"><a href="../../../h/e/p/Hepatitis.html" title="Hepatitis">Hepatitis</a>&#160;| <a href="../../../c/i/r/Cirrhosis.html" title="Cirrhosis">Cirrhosis</a>&#160;| <a href="../../../n/o/n/Non-alcoholic_steatohepatitis.html" title="Non-alcoholic steatohepatitis">NASH</a>&#160;| <a href="../../../p/r/i/Primary_Biliary_Cirrhosis_8cd5.html" title="Primary Biliary Cirrhosis">PBC</a>&#160;| <a href="../../../p/r/i/Primary_sclerosing_cholangitis.html" title="Primary sclerosing cholangitis">PSC</a>&#160;| <a href="../../../b/u/d/Budd-Chiari_syndrome_16b9.html" title="Budd-Chiari syndrome">Budd-Chiari</a>&#160;| <a href="../../../h/e/p/Hepatocellular_carcinoma.html" title="Hepatocellular carcinoma">Hepatocellular&#160;carcinoma</a>&#160;| <a href="../../../a/c/u/Acute_pancreatitis.html" title="Acute pancreatitis">Acute&#160;pancreatitis</a>&#160;| <a href="../../../c/h/r/Chronic_pancreatitis.html" title="Chronic pancreatitis">Chronic&#160;pancreatitis</a>&#160;| <a href="../../../h/e/r/Hereditary_pancreatitis.html" title="Hereditary pancreatitis">Hereditary pancreatitis</a></td>
</tr>
<tr>
<th style=""><a href="../../../s/m/a/Small_intestine.html" title="Small intestine">small intestine</a>:</th>
<td style="" colspan="1"><a href="../../../p/e/p/Peptic_ulcer.html" title="Peptic ulcer">Peptic&#160;ulcer</a>&#160;| <a href="../../../i/n/t/Intussusception_%28medical_disorder%29.html" title="Intussusception (medical disorder)">Intussusception</a>&#160;| <a href="../../../m/a/l/Malabsorption.html" title="Malabsorption">Malabsorption</a>&#160;(e.g.&#160;<a href="../../../c/o/e/Coeliac_disease.html" title="Coeliac disease">coeliac</a>, <a href="../../../l/a/c/Lactose_intolerance.html" title="Lactose intolerance">lactose&#160;intolerance</a>, <a href="../../../f/r/u/Fructose_malabsorption.html" title="Fructose malabsorption">fructose&#160;malabsorption</a>,&#160;<a href="../../../w/h/i/Whipple%27s_disease.html" title="Whipple's disease">Whipple's</a>)&#160;</td>
</tr>
<tr>
<th style=""><a href="../../../c/o/l/Colon_%28anatomy%29.html" title="Colon (anatomy)">colon</a>:</th>
<td style="" colspan="1"><a href="../../../d/i/a/Diarrhea.html" title="Diarrhea">Diarrhea</a>&#160;| <a href="../../../a/p/p/Appendicitis.html" title="Appendicitis">Appendicitis</a>&#160;| <a href="../../../d/i/v/Diverticulitis.html" title="Diverticulitis">Diverticulitis</a>&#160;| <a href="../../../d/i/v/Diverticulosis.html" title="Diverticulosis">Diverticulosis</a>&#160;| <a href="../../../i/n/f/Inflammatory_bowel_disease.html" title="Inflammatory bowel disease">IBD</a>&#160;(<a href="../../../c/r/o/Crohn%27s_disease.html" title="Crohn's disease">Crohn's</a>,&#160;<a href="../../../u/l/c/Ulcerative_colitis.html" title="Ulcerative colitis">Ulcerative&#160;colitis</a>)&#160;</td>
</tr>
</table>

<!-- 
Pre-expand include size: 144936 bytes
Post-expand include size: 62019 bytes
Template argument size: 45354 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../b/i/o/Biological_therapy_for_inflammatory_bowel_disease.html">http://en.wikipedia.org../../../b/i/o/Biological_therapy_for_inflammatory_bowel_disease.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Category</a>: <span dir='ltr'><a href="../../../g/a/s/Category%7EGastroenterology_aaa2.html" title="Category:Gastroenterology">Gastroenterology</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../b/i/o/Biological_therapy_for_inflammatory_bowel_disease.html">Article</a></li><li id="ca-talk"
	       	       ><a href="../../../b/i/o/Talk%7EBiological_therapy_for_inflammatory_bowel_disease_3618.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Biological_therapy_for_inflammatory_bowel_disease">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 13:52, 3 April 2007 by Wikipedia user <a href="../../../c/r/o/User%7ECrohnie_e91b.html" title="User:Crohnie">Crohnie</a>. Based on work by Wikipedia user(s) Statesman 88, <a href="../../../s/a/m/User%7ESamir_8997.html" title="User:Samir">Samir</a>, M dorothy, <a href="../../../c/m/d/User%7ECmdrObot_0605.html" title="User:CmdrObot">CmdrObot</a>, <a href="../../../b/w/h/User%7EBwhack_e9d6.html" title="User:Bwhack">Bwhack</a>, <a href="../../../e/u/c/User%7EEuchiasmus_e847.html" title="User:Euchiasmus">Euchiasmus</a>, <a href="../../../b/t/y/User%7EBtyner_9437.html" title="User:Btyner">Btyner</a>, <a href="../../../s/h/a/User%7EShanel_222a.html" title="User:Shanel">Shanel</a> and <a href="../../../b/o/s/User%7EBostonMA_1634.html" title="User:BostonMA">BostonMA</a>.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
